Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders
Objective
To determine the effect of maintenance obinutuzumab on duration of complete response (CR) in patients with CD20+B-cell PCNSL who attain CR to first-line treatment with high-dose methotrexate-based chemotherapy.